GSK vs PHAR
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jul 03, 2026
GSK
PHAR
Investment Advisor Scores
PHAR
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | PHAR | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 21.5054 | 24.2131 | GSK |
| PEG Ratio | 19.3637 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 1.5% | -8.4% | GSK |
| Earnings Growth | 8.4% | 104.2% | PHAR |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 66.2/100 | 55.1/100 | GSK |
| Profit Margin | 17.8% | 3.3% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | BUY | HOLD | GSK |